European Alternative logo
Discover Alternative to... News
← Back to news

Lexroom raises $50M, putting two European labs in the global legal-AI race

Milan-based Lexroom's Series B lands six months after Legora's $5.6B valuation, giving Europe two credible alternatives to Harvey in one of AI's most contested verticals.

Italian legal-AI startup Lexroom closed a $50M Series B led by Left Lane Capital on 19 May 2026, eight months after its $19M Series A. The round will fund expansion into Spain and Germany on top of the company’s Italian base, where it already serves more than 8,000 law firms.

The raise lands six months after Stockholm-based Legora extended its Series D at a $5.6B valuation, with new investors including Nvidia’s NVentures and Atlassian joining Accel, Redpoint, and Bessemer. Legora has crossed $100M ARR and counts Linklaters, Barclays, and White & Case among its customers.

The category they share is the most-watched professional-services AI vertical. US-based Harvey raised at an $11B valuation in March 2026 in a $200M round co-led by GIC and Sequoia, and is embedded at most of the AmLaw 100. Microsoft’s acquisition of UK contract-AI startup Robin AI in late March pulled a third European candidate off the table.

Legora and Lexroom approach the same workflows — research, drafting, document review — from opposite ends of European legal practice. Legora leans common-law and has won UK and Nordic firms with collaborative chat-based workflows. Lexroom is purpose-built for civil-law jurisdictions, indexing 6M+ verified European legal sources (legislation, case law, regulatory texts) with strength on Italian and Spanish documents that Harvey has historically underserved.

For European law firms, the practical effect is that the “Harvey alternative” question is no longer hypothetical: there are now two well-funded peers with real customer rosters and complementary jurisdictional strengths.

For the broader European tech case, legal AI joins a small set of AI sub-categories (image generation, coding agents) where European labs are clearly in the global top three rather than playing catch-up.